ABSTRACT
Understanding the evolution of SARS-CoV-2 virus in various regions of the world during the Covid19 pandemic is essential to help mitigate the effects of this devastating disease. We describe the phylogenomic and population genetic patterns of the virus in Mexico during the pre-vaccination stage, including asymptomatic carriers. A RT-qPCR screening and phylogenomics reconstructions directed a sequence/structure analysis of the Spike glycoprotein, revealing mutation of concern E484K in genomes from central Mexico, in addition to the nationwide prevalence of the imported variant 20C/S:452R (B.1.427/9). Overall, the detected variants in Mexico show Spike protein mutations in the N-terminal domain (i.e., R190M), in the receptor-binding motif (i.e., T478K, E484K), within the S1-S2 subdomains (i.e., P681R/H, T732A), and at the basis of the protein, V1176F, raising concerns about the lack of phenotypic and clinical data available for the variants of interest (VOI) we postulate: 20B/478K.V1 (B.1.1.222 or B.1.1.519) and 20B/P.4 (B.1.1.28.4). Moreover, the population patterns of Single Nucleotide Variants (SNVs) from symptomatic and asymptomatic carriers obtained with a self-sampling scheme confirmed the presence of several fixed variants, and differences in allelic frequencies among localities. We identified the mutation N:S194L of the Nucleocapsid protein associated with symptomatic patients. Phylogenetically, this mutation is frequent in Mexican sub-clades, so we propose an additional VOI, 20A/N:194L.V2 (B.1.243). Our results highlight the dual and complementary role of Spike and Nucleocapsid proteins in adaptive evolution of SARS-CoV-2 to their hosts and provide a baseline for specific follow-up of mutations of concern during the vaccination stage.
IMPACT STATEMENT Following self-sampling, screening of mutations of concern, and a combined phylogenomic and population genetics pipeline, we reveal the appearance of three VOI with mutations in the Spike protein, P.4 (B.1.1.28.4) and 20B/478K.V1 (B.1.1.222, leading to B.1.1.519), and in the Nucleocapsid protein, 20A/N:194L.V2 (B.1.243), in Mexico during the pre-vaccination stage. The mutation S194L in the Nucleocapsid was found to associate with symptomatic patients versus asymptomatic carriers in the population investigated. Our research can aid epidemiological genomics efforts during the vaccination stage in Mexico by contributing with a combined analytical platform and information about variants within different genetic lineages with the potential to evolve into variants of concern (VOC).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
There was no critical trial
Funding Statement
This was funded by a Mexican CONACYT 2020-COVID19 grant to Angelica Cibrian.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical committee clearance. All the RNA samples that are reported in this study were obtained during a surveillance program part of a research protocol compliant with El Comite de Bioetica para la Investigacion en Seres Humanos del Centro de Investigacion y Estudios Avanzados del IPN (COBISH) led by Dr. Betzabe Quintanilla Vega, who approved research for all SARS-CoV-2 carriers in the State of Guanajuato (069/2020). The samples from the State of San Luis Potosi were obtained through the clinical diagnostic service provided by the Centro de Investigacion en Ciencias de la Salud y Biomedicina of the Universidad Autonoma de San Luis Potosi as part of a research protocol compliant with the corresponding local authorities, represented by Dra. Liliana Rangel Martinez according to the Ley Estatal de Salud and NOM-012-SSA3-2012, who approved obtaining and using the samples for this paper (SLP/09-2020). For samples from Jalisco the Laboratory for the Diagnosis of Emerging and Reemerging Diseases (LaDEER), the University of Guadalajara, was compliant with local ethical authorities. Obtaining and using research samples from Jalisco were approved by the Comites de Investigacion, Etica en Investigacion y Bioseguridad de la Universidad de Guadalajara led by Dra. Barbara Vizmanos Lamonte CI- 00821 and CI-00721). Moreover, all samples were treated and contained by international standards of Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19), and all positive diagnostics were informed to patients and the corresponding Health local authorities between 24 and 48 hours of sampling. An informed written consent for the use of surveillance samples was obtained from all patients.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We modified the title and updated the name of the variants according to the new nomenclature by the OMS. We streamlined the discussion for clarity. The rest of the paper and figures remain the same, and the message of the paper has not changed.
Data Availability
All data is available in public databases.
http://www.ira.cinvestav.mx/ncov.evol.mex.aspx
